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Abstract
Introduction
Prevalence of early-stage breast cancer is increasing with the aid of preventative screenings and
early diagnosis. The standard of care is transforming from conventional approaches with long
treatment regimens towards hypofractionation and tissue sparing techniques. Based on studies
over the past ten years, there are reasons to consider a partial-breast, hypo fractionated treatment
option in the supine position. In practice, aPBI is often produced using several static intensity
modulated beams to control dose to the normal breast tissue and limit dose to the heart and lungs.
Patients may also be treated in the prone treatment setup in order to maximize the potential for
tissue and organ sparing. These techniques: accelerated partial breast irradiation and prone
treatment planning, combined, can conclude whether patients with early-stage breast cancer can
benefit from furthering research and treatment planning in this modality.
Methods
This study gathers ten patients and uses their anonymized data scans to formulate a retrospective
analysis comparing static IMRT and IMRT VMAT plans for evaluating dose to the heart, lungs,
contralateral breast and affected breast tissue. Planning target volumes that coincide with the
aPBI recommendations for treatment are created based on the tumor bed. Beam arrangements
and plans are created with ALARA in mind and dose constraints based on a phase III study
called the Florence Trial.
Results
Results were analyzed from SPSS data outputs and Wilcox sign rank tests. Tests ran show
statistically significant lower dose to heart, lungs, and contralateral breast in the Static IMRT
treatment plans compared to the VMAT IMRT plans.
Conclusion
The current method of using static IMRT fields has the lowest overall dose to the heart, lungs,
contralateral breast, and normal breast tissue due to the ability to control the entrance and exit
dose. The VMAT plans produced acceptable homogenous dose to the PTV but were statistically
higher in dose due to the inability to prevent exit dose in critical organs at risk. This is partially
due to the minimum arc length limitations, the need to cover the PTV and control high dose,
clearance limitations for beam angles, and patient anatomy. Static IMRT beam arrangements
would be beneficial for treating patients in the prone position.
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Introduction
An American woman has a one-in-eight chance of developing breast cancer in her lifetime 1.
The yearly incidence of breast cancer is increasing partly because of the advancements in
screening and early diagnosis2. With the advancement of screening methods, a majority of
patients present with early-stage breast cancer 2. As more women are diagnosed with early stage,
breast conservation treatment techniques are being studied, and long-term outcomes are tracked
to improve survivability while maintaining the quality of life with function and cosmetic regard.
The path to early-stage diagnosis is thorough. Upon discovery of a mass, a patient
undergoes an ordered process to confirm diagnosis and plan for curative treatment. The patient
has a history and physical obtained. The physical examination allows the physician to visualize
the extent of the cancer and the location. The patients' health and familial history are collected
and provide insight into disease characteristics, whether it runs in the family, aligns with other
diagnoses, is hormones related, and whether genetic predisposition applies. The patient will have
a mammogram, followed by a tissue biopsy and pathology assessment where there will be a
definitive hormonal determination; ER, PR, HER2 positivity, or lack thereof. A patient may also
undergo an MRI if the physician advises, which assists with diagnosis and treatment planning.
This information combined aids in the determination of a consistent diagnosis of the disease to
provide a direction for management and comparable treatment outcomes3. The National Cancer
Institute (NCI) defines early-stage breast cancer as a cancer that has not spread beyond the breast
or into the regional lymphatics4. Early-stage would include ductal carcinoma in situ, stage I,
stage IIa, stage IIB and stage IIIA breast cancers4.
As the surgical standard of care has progressed from William Halsted's 1884 technique of
the radical mastectomy to the modern-day lumpectomy for early stage and standard mastectomy
3

for later stages, so too advancements have been made in the field of radiation oncology 5. For
patients with early-stage breast cancer, the goal is to minimize the long-term effects of surgery
and radiation by giving alternatives to previous radical measures. The combination of breastconserving surgery and radiation therapy will aid in producing the desirable outcomes of
reducing the risk of metastasis or local recurrence, maintaining cosmesis, relieve symptoms, and
return to the quality of life one had before diagnosis all while maintaining survival rate 6. In
addition to staging, some studies characterized patients as low risk of recurrence to consider
whether a more conservative approach would benefit the patient. To characterize a patient as low
risk, tumor characteristics are evaluated by their ER/PR positivity, HER2 negativity, and p53
negativity, along with physical evaluation of being non-palpable and node negative 15. These
factors are considered low risk due to the favorable recurrence-free survival rates over a fifteenyear period15. Breast conservation treatment options may be offered if the patient meets the
criteria for early-stage cancer with a low risk of recurrence. As patient diagnosis progresses with
earlier detection and thorough evaluation of tumor characteristics, breast conservation techniques
may evolve as the standard for treatment.
There are multiple techniques for patient setup in each position, based on available
equipment and patient anatomy. Although it may be ideal in some cases to treat patients in a
prone position based on study data, It is important to properly assess and position the patient for
an optimal treatment outcome. Patients are assessed upon consultation, and the physician will
decide the most suitable positioning. Patient setup position can depend on anatomy, disease
location, patient age, body habitus, and physical capabilities or limitations that could prevent
them from being in a particular position due to mobility or injury because there are multiple
positions and modalities to consider. Patients with large, pendulous breasts often benefit and are
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ideal in the prone setup position. This allows the affected breast to remain suspended away from
the body, protecting normal tissues and critical structures such as the heart, from additional
radiation dose while keeping the breast itself from laying in a way it would cause excess skin
folds or too much movement to be reproducible day-to-day. This position is optimal for
assessing the toxicity and dose to the critical structures we will be comparing in our study. This
study aims to retrospectively compare IMRT v VMAT aPBI for patients previously treated
conventionally in the prone position.

Literature Review
Studies done by The National Surgical Adjuvant Breast and Bowel Project have found
that in the treatment of stage I and II breast cancer, long-term results of those with breast
conservation were comparable to those of patients who had total mastectomies 6. Although the
overall tumor control was comparable, the risk of recurrence increased in patients that did not
elect to have radiation therapy6. This information suggests it is ideal for treating early-stage
breast cancer patients with multiple modalities such as surgery followed by hypo-fractionated
treatment schemes, interstitial brachytherapy, Intensity modulated therapy, and accelerated
partial breast irradiation (aPBI). There are various treatment combinations available that have the
potential to increase long-term survival outcomes and tumor control.
Medical professionals have intensively studied accelerated partial breast irradiation for
years in multiple phases II and III trials involving 3-dimensional conformal and intensity
modulated radiotherapy. More researchers are concluding post-patient follow-up of about 60 to
90 months that the benefits of aPBI outweigh any minimal risk of toxicity or late side effects,
especially compared to the normal tissue dose with whole breast irradiation 7,8. To evaluate these
5

toxicity effects, researchers conducting a phase II trial on 3-DCRT aPBI did a self-assessment of
breast appearance and toxicity based on the National Cancer Institute Common Terminology
Criteria for Adverse Events, version 3.08. The values evaluated in this scoring represented effects
of skin atrophy, hyperpigmentation, erythema, fibrosis, skin indentations and other significant
effects7. These scored values are assessed in different grade levels, 1 through 5. 86% of patients
were satisfied with their treatment outcomes three years post-treatment. Of toxicity reporting,
there was a 5.8% rate of grade 3 toxicities, including fibrosis and dermatitis, with no grade 4 or 5
toxicities. Overall, 36.5% of patients in the study reported grade 1, and 50% of patients reported
grade 2 toxicities7. The results of this study found that overall satisfaction with the aPBI
treatment was 100%, and patients would choose aPBI as their treatment option again.
A seven-year phase II trial comparing aPBI using 3DCRT and Image guided intensity
modulated radiation therapy (IG-IMRT) for breast conservation treatment compares similar
treatment toxicity outcomes and patient satisfaction post-treatment follow-up and recommends
aPBI treatment modality as a valid alternative to the WBI technique 8. Of the 60 patients enrolled
and treated with the IG-IMRT, no grade 2 or higher acute side effects were recorded, and only
1.9% of patients experienced grade 2 erythema. One hundred percent of patients treated with IGIMRT recorded excellent or good cosmetic outcomes 8. Patients tolerate the accelerated
fractionation as well as a conventional course without the consequence of increased toxicity or
worse cosmesis8.
This treatment method is typically used for high-risk areas of recurrence in a small
volume of breast tissue for early-stage breast cancers. Due to the small volume being irradiated,
the treatment schedule can be much shorter than traditional fractionation schemes while utilizing
high radiation doses. This treatment approach does not encompass the entire affected breast9.
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The aPBI treatment course can be fabricated using 3D conformal beam arrangements,
field-in-field techniques, static IMRT fields, and volumetric modulated arc therapy (VMAT).
The difference is the target volume and fractionation schedule, not the technique itself.
The outcomes have been compared based on hundreds of patients in multiple studies. If
cosmesis, overall tumor control, and patient quality of life is at a suitable level, it is worth
looking into expanding on these ideas that were originally founded with the potential to shorten
treatment times, potential costs, and emotional stress for some women undergoing treatment 10. It
is not for every patient with breast cancer, though; there are limitations to these studies.
Limitations of aPBI consideration are suitable for patients with a tumor less than 2.5cm in
diameter, over 40 years old, and with an early-stage breast cancer diagnosis 11. The patients also
need to have surgical clips placed in their tumor bed at the time of their surgery. These clips are
crucial to the planning process, as the margins are expanded from them. Standard clinical target
volume for aPBI is derived from a uniform 15mm expansion on the clips, or 20mm of the
surgical cavity. Depending on the area, the CTV must not be within 5mm of the skin. The PTV is
10mm expanded from the CTV. The PTV should be modified if necessary to exclude 5mm
below the skin's surface and not extend into the chest wall or pectoralis muscle. Other
modifications may be considered depending on the physician and the location of the tumor bed
site. This is the target to be used for aPBI planning, which in comparison to the WBI guidelines,
are much smaller. The target volumes remain the same for static IMRT, 3D, or VMAT IMRT
aPBI.
Evaluation of long-term results has impacted considerations of treating early-stage breast
cancers with aPBI. A study at Florence University in Florence, Italy, concluded that compared to
conventional WBI, accelerated partial breast irradiation using static IMRT had similar if not
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more favorable outcomes in local tumor control, cosmesis, fatigue, and overall quality of life
after ten years12. The Florence trial is an example of one randomized phase III trial that aimed to
assess whether aPBI would be a safe and effective alternative for whole breast irradiation. The
goal was to prevent or improve treatment-related toxicity over the long term while introducing a
hypo-fractionated, tissue-sparing alternative to conventional methods, and so IMRT techniques
were used in the aPBI arm during their comparison11. Researchers compared a conventional WBI
course of 50Gy in 25 fractions with an aPBI course of 30Gy in 5 once-daily fractions over a total
of five hundred and twenty patients. Tangential fields with wedges were produced for the WBI
arm, and five step-and-shoot IMRT fields were used for the aPBI arm. Plans were then optimized
for coverage of the PTV to have 100% of the PTV receiving 95% of the dose. A maximum of
105% to the PTV and a minimum of 28Gy. OAR considerations were that uninvolved breast: not
> 50% received a dose of > 50% of the prescribed dose (V15 < 50%); ipsilateral lung, not > 20%
received a dose > 10 Gy (V10 < 20%); contralateral lung, not > 10% received a dose > 5 Gy (V5
< 10%); contralateral breast, maximal dose < 1 Gy; and heart, not > 10% received a dose > 3 Gy
(V3 < 10%). All patients had follow-up care to assess recurrence and safety endpoints. In the ten
years, there were no significant differences in risk between groups. Patients reported favorable
cosmesis, and more patients reported fair or poor cosmesis from the WBI arm. 14% of patients
rated fair outcome in the WBI arm compared to 0.8% of aPBI arm. The once-daily aPBI
schedule may influence the low toxicity findings compared to the BID schedule of other studies.
This study has found aPBI to be a reasonable option for treating patients with early-stage breast
cancer12.
A phase I/II study has assessed twenty post-menopausal women with node-negative
breast cancer with tumors less than 3.0cm to have tolerated prone aPBI using IMRT 13. The study
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resulted in good conformality and low toxicity 13. Potential advantages for treating in the prone
position to include a reduction in intrafraction motion, primarily due to the decrease in
respiratory and chest wall motion, and excluding more of the chest wall, heart and lung 13. This
reduction of dose to those structures that may not have been attainable in the supine position.
Patient follow-up reported good cosmetic results and minimal recurrence rates one-year post
treatment13.
In contrast, a phase I prospective study at the University of Michigan assessed whether
aPBI with breath-hold IMRT treatments would be effective in the supine position, with adverse
results14. Many patients experienced unacceptable (fair or poor) cosmesis described in detail in
their results14. Results such as these may promote the continuation of conventional fractionation
and whole breast irradiation in many departments and steer clinicians from using hypofractionation or alternative modalities. When considering treatment plans done in studies on
prone and supine, and based on anatomical knowledge, it may be reasonable to consider the
difference in normal tissue treated in each plan design. Planning in the prone position may
control normal tissue toxicity and poor cosmetic outcomes.
Results from previous studies have shown favorable results in the supine position using
multi-modalities. More recently, research has shown positive results over the past decade for
treating aPBI in the supine position. Since studies such as the Florence trial have supported
evidence that aPBI is beneficial, this study is to expand the potential and consider additional
advantages in a prone patient population. A combination of prone patient positioning and
utilization of aPBI may support optimal patient outcomes in the future of breast-conserving
radiation therapy. The purpose of this study is to further research the potential benefits of IMRT
aPBI by comparing static IMRT fields to VMAT IMRT in the prone position.
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Methods and Materials
Patient Selection
Ten patients treated at ProMedica Flower Hospital between 2017 and 2022 for earlystage breast cancer were selected for a retrospective analysis of the dose delivered to their
normal tissue, organs at risk, and tumor bed. Criteria for selecting patients were small, local
tumors under 2.5 centimeters in diameter that have not involved the lymphatics or the skin and
do not require treatment to encompass those areas.
Planning Target Volumes for aPBI
The tumor bed was delineated by assuming clips would have been placed at the time of
surgery and to be expanded on per the contouring guidelines of the study. Once the center of the
tumor bed was determined, a 1.0 cm CTV margin surrounds the central tumor bed, followed by
an additional 1.0cm PTV. These margins have been cropped 3mm from the skin where needed.
This results in the best replication of previous supine aPBI studies and the methods used in the
Florence University trial. The prescription is a dose of 30Gy in 5 nonconsecutive fractions.
Materials
This study is partial to patients simulated in the prone treatment setup position. The
patients included have been simulated on a prone breast board on the CT table. The affected
breast has been positioned through the opening on the board and marked for reproducibility.
There is a single cushion for comfort placed under the patients' ankles. Both arms are up,
grasping pegs at the top of the board. A moveable head cushion is situated to allow a comfortable
position for the head to lay, keeping in mind the chin position to ensure it is not tilted towards the
treatment area. Each patient is scanned once to check for the initial level and straightness on the
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table. Adjustments are made if needed at this point. Then a second scan is performed with 3mm
slices for optimal body and tumor delineation and planning outcomes on the Eclipse treatment
planning software. The scan range is selected from the mandible through the thorax down to 5cm
past the inframammary fold. The physician then places a 3D mapped isocenter on the scan to
indicate the center of our tumor bed, and this virtual point is displayed on the patient's skin using
a Lap Laser system connected to the software, transmitting the same coordinates from within the
images to a specific point on the patient. Once these marks have been placed, the patient's data is
sent to the Eclipse planning software, and the patient is ready to be imported for planning.
IRB
Patients selected have been converted to anonymous data sets to be planned upon and
labeled in a random order as ‘Patient 1’ through ‘Patient 10’. Each patient then has a tumor bed
delineated to fit the needs of the Florence trials protocol as stated above. All patient identifiers
have been removed from treatment planning software. This study has little to no risk for patient
privacy intrusions. This study was also approved by the Grand Valley State University IRB
board.
Planning aPBI
Patients were then planned using five static coplanar IMRT fields; one patient had six
fields due to anatomical limitations to meet the constraints for global max, organ dose, and PTV
coverage. Those same patients have an optimal VMAT plan made using the same aPBI PTV
tumor bed target structure. This plan comprises two or four partial-arcs to ensure adequate PTV
coverage (Figures 1. and 2. show beam arrangement for both plans, on study patients 3 and 5).
Both the IMRT VMAT and static IMRT plans are optimized to have 100% of the treatment dose
covering 95% of the PTV, and a minimum of 28Gy on the PTV, also adding a 105% maximum
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dose constraint. Eclipse planning software is used to produce these treatment plans with Version
15.6, with calculation model AcurosXB_15604, version 15.6.04. The clinic's TrueBeam linear
accelerator with 6MV energy has been chosen for treatment for all patients and to utilize the Qfix
Prone Breast board, which inserts into the treatment couch of that machine to provide attainable
gantry angles and lessen clearance issues.
Comparisons are made for each anonymized patient and their IMRT plans using the
given dose constraints and modified dose constraints which were established due to the limited
dose given to the OARs once the plan was evaluated. This will include the dose to the heart,
lungs, contralateral breast and uninvolved tissues of the affected breast. The dose constraints are
as follows: The max dose to the PTV should be under 105% of the prescription, if possible, this
was not achievable for the VMAT study which will be discussed further in the results section;
the minimal dose to the PTV 28Gy; Contralateral breast is less than 1 Gy; heart 10% not
receiving more than 3Gy; ipsilateral lung not 20% receiving over 10Gy, per trial standards. This
study has been modified to observe the dose to the same OARs but looking at the maximum dose
to those structures due to the miniscule value when evaluated on the study standards. The
additional dose constraints and comparisons for this study are evaluated on the DVH and
recorded into an excel spreadsheet; D2cc of the ipsilateral and contralateral lung, max dose to
ipsilateral and contralateral lung, max dose to the contralateral breast to be under 1Gy, maximum
heart dose, mean heart dose, and mean dose to normal breast tissue of the affected side. The dose
homogeneity will also be compared. All plans have been generated using proper judgment and
ALARA standards, meaning the beam arrangements will minimize direct trajectory with critical
structures and will follow dose constraints for heart, lungs, and breast tissue accordingly.
Statistical Methods
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Ten patients are planned and evaluated as if intended to treat. The dose characteristics are
compared between groups using Wilcox signed rank test, as appropriate due to the small study
size of less than 30 participants and assumed non normal means. All p values of <.05 were
considered significant. Statistical analysis done using IBM SPSS Statistics 26.0 software.

Results
Breast cancer patients can benefit from multiple treatment positions and modalities to
reduce toxicity to the heart, lungs, and normal breast tissue, preventing complications in the
future. The goal of this study is to evaluate the differences between the static IMRT and VMAT
groups to determine which modality is the optimal treatment for patients treated aPBI in the
prone position. Ten patients were chosen for this study and planned to use both treatment
options. All planning target volumes were under 2.5cm in diameter per protocol yet varied in
location to the chest wall and breast size.
Ipsilateral lung:
The lungs were contoured using the Eclipse 'segmentation wizard' tool for each patient in
the study. When possible, the lungs were avoided to prevent unnecessary dose, but for VMAT, it
is impossible to avoid the lung altogether. The dose to 2cc of the ipsilateral lung ranged from
1.6cGy to 740cGy over both the static IMRT and VMAT plans. The mean dose to the ipsilateral
lung ranged from 205cGy to 343cGy. Sign rank test indicates the higher dose to the lung is with
the VMAT plan compared to the static plan, p = 0.028.
Contralateral lung:
The contralateral lung was contoured and evaluated on the DVH. Though the
contralateral dose is expected to be lower due to the increased proximity from the affected breast
13

and target volume, as before, there will still be an unavoidable exit dose on VMAT planning.
The dose to the contralateral lung ranges from 1.5cGy to 325cGy over both plans. The mean
dose for the static IMRT plans is 43.4 cGy whereas the mean dose for the IMRT VMAT plans is
166cGy. The max dose to the lung is 263cGy for the static IMRT plan and 325cGy for the
VMAT plan. This is a significant difference indicated by the sign rank test in favor of the static
IMRT plan, p = 0.037 and p= 0.028, respectively.
Heart
The heart is a critical organ at risk for breast cancer treatments. Overdosing the heart can
lead to complications such as cardiac failure. The proximity of the heart to the affected breast
and field setup has shown to provide a variety of dose to the heart from patient to patient. The
mean dose to the heart should be as low as possible, and the maximum dose to the heart should
not have more than 10% receiving 3Gy. The maximum dose to the heart in this study ranges
from 3.90cGy to 1247cGy. The average maximum dose for the static IMRT plans was 154cGy
whereas the average maximum dose to the heart in the VMAT plan is 460cGy. Each planning
technique's mean dose to the heart ranges from 1.3cGy to 216cGy. The average mean dose for
static plans is 11.8cGy, and the average dose to the heart for the IMRT plans is 101cGy. There is
a significant difference in maximum heart dose and mean heart dose. The static IMRT plan is
significantly less dose to the heart in both mean and max constraints. P = 0.013 and p=0.005. The
dose comparison can be seen in figure 3.
Contralateral Breast Max
Typically, a physician will delineate a contralateral breast contour to monitor the dose
accumulated during treatment of the opposing breast. The prone patients in this study did not
have contralateral breast contours drawn due to the placement of that breast during patient setup
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at simulation. The breast is pulled out and away from the treated breast while lying on the patient
support device. In a 3-dimensional conventional breast treatment, the fields are placed not to
include that breast tissue. For this study, a breast contour was drawn by the researcher and
evaluated on the DVH due to the fields potential to involve that tissue. The Florence trial
includes a maximum dose of 100cGy to the contralateral breast in the treatment planning
constraints. Compared to the plans created in the Florence study, these constraints were met to
the best of the treatment planning ability for the static IMRT plans. Due to the IMRT VMAT
plans' geometry, it was impossible to meet this constraint. The dose to the contralateral breast
range from 5.90cGy to 431cGy for both treatment plans. The average max dose for the static
IMRT plans is 54.4cGy and 292cGy for the IMRT VMAT plans. A sign rank test indicates a
significant difference in maximum dose to the contralateral breast. The max dose is significantly
lower in the static IMRT plans. p = 0.05.

Discussion
This study aims to evaluate the potential toxicity of normal breast tissue and organs at
risk while treating early-stage breast cancer patients with two different IMRT treatment
modalities. The primary organs at risk for patients with breast cancer are the heart, both lungs,
and contralateral breast. Keeping a limited dose to these structures ensure the patient does not
develop long-term complications such as heart disease, pulmonary issues, tissue complications,
and fibrosis.
The lungs receive a lower dose during a prone setup position due to the distance from the
target volume and how the breast tissue falls from the chest wall. The beams do not intersect the
chest wall as they would for a supine tangential setup, providing a lower dose to the lung. The
15

dose evaluated from the comparison plans in this study shows a relatively low dose accumulation
regarding the mean dose to the lungs. The static IMRT plans will provide the lowest dose to the
lungs because the beams avoid entry and exit on the contralateral breast and lung when possible.
If a patient has a tumor bed close to the chest wall, the beam arrangement may include more
lungs than a patient with a tumor bed located more anterior and further away from the chest wall.
The VMAT plans will provide dose to both lungs as they must exit through those structures to
meet a reasonable arc range and provide coverage to the aPBI PTV.
The heart falls behind the chest wall in the prone position. It is the thought that although
the heart falls forward, the breast tissue and tumor bed would fall further, providing enough
room to reduce the involvement of the heart and lungs in the beam arrangement. The mean heart
dose was considerably lower with the static IMRT planning, possibly due to the ability to avoid
the heart completely. Even though the static IMRT plan was lower, the mean heart dose in the
VMAT IMRT plans would still be acceptable in many clinics, with the mean dose to the heart at
1Gy. Patients who are treated for right-sided breast cancer may have lower heart doses as well.
One plan with shallow target and max and mean dose to the heart increased with VMAT (1.0 cm
and medial from chest wall on patient 6).
The recommended study constraints dictate that a contralateral breast cannot receive 1Gy
or more to qualify for aPBI treatment. That was impossible to achieve with the VMAT IMRT
planning due to the exit dose on the breast. This may be the main limitation to providing aPBI in
a VMAT modality.
Planning involved realistic treatment expectations regarding the number of beams, angles
used, and arc lengths. The goal was to create treatment plans that would be treatable on the
Truebeam and using the Qfix prone breast board. The plans should also provide angles that
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would not require intervention from the treating therapist or concern for clearance when treating
the arc therapy. Due to the planning techniques used in an attempt to control the high dose in the
treatment area, the VMAT plans would have a longer treatment time, requiring two arcs per side,
and the therapist would most likely have to rotate in the room to go from one side to the other for
clearance reasons. This may reduce interest in a VMAT planning technique in the prone position.
However, a supine IMRT VMAT treatment plan would not have the same limitations and
perhaps should be considered in future studies.

Limitations and Future Research
Limitations of this research study include the limited availability of patients being treated
in the prone position at this institution. It is for that reason, only ten patients are being compared
in this study, limiting the range of data to be compared. Also, it would have been ideal to have
the affected breast be consistent throughout the study with all patients, but with the limitation, it
was necessary to include both left and right-sided breast patients. Due to the proximity of the
heart to the left breast, the dose to the heart is expected to be higher on left-sided breast patients.
This can skew the comparison from patient to patient.
This treatment approach also requires a specific planning target volume which relies on
surgical placement of markers in the tumor bed. Since these patients were not intended to be
treated with aPBI, the target volumes had to be assumed by the researcher and meet the criteria
for planning.
Lastly, a prone patient setup requires an additional patient positioning device placed on
the tabletop and positions the patient higher than the treatment couch itself, requiring the table to
be in a lower position for isocenter placement and treatment. The result is a limited range of
17

motion for the gantry of the linac to move about the patient while treating. This limits the range
of the treatment arcs selected for the patient, making it difficult to devise an optimal plan. See
figure 1 for beam configuration. IMRT VMAT treatment approach requires a minimum arc
geometry to deliver monitor units appropriately, and in order to successfully construct a
treatment plan, multiple arcs were used, which would make for a longer treatment time.
Further research may include considering other treatment positioning devices, if possible,
or studying a patient population in a supine treatment position and comparing the organ dose
constraints. It would also be beneficial to study a larger patient population and group the patients
by affected breast before analyzing the dose data.

Conclusion
In summary, patients with early-stage breast cancer can benefit from aPBI techniques
when treated in 5 nonconsecutive once-daily treatments. Care must be taken to ensure that the
heart, lungs, and unaffected breast do not receive a significant dose. For patients in the prone
position, it would be possible to treat static IMRT fields while meeting the dose conditions of
past studies. This study was a brief representation of the possibilities of treating prone patients
with aPBI, and it may be beneficial to see further studies analyze a larger patient population.
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Figure 1. Beam configuration for static IMRT (left) and IMRT VMAT (right) for one study subject.
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Figure 2. Beam configuration for a patient with a proximal tumor bed.

Figure 3. Boxplot representing the comparison of mean heart dose between the static IMRT and
VMAT plans. There is significantly higher dose using the VMAT plan.
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